Coherus BioSciences, Inc. (CHRS) Insider Sells $263,375.70 in Stock

Coherus BioSciences, Inc. (NASDAQ:CHRS) insider Alan C. Herman sold 17,535 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $15.02, for a total transaction of $263,375.70. Following the completion of the transaction, the insider now owns 49,651 shares in the company, valued at approximately $745,758.02. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of Coherus BioSciences, Inc. (CHRS) opened at 11.65 on Friday. The stock has a 50 day moving average of $13.61 and a 200 day moving average of $19.60. The company’s market cap is $598.18 million. Coherus BioSciences, Inc. has a 1-year low of $10.80 and a 1-year high of $31.98.

Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.21. The business had revenue of $1.40 million during the quarter. Coherus BioSciences had a negative return on equity of 307.41% and a negative net margin of 73.89%. Analysts predict that Coherus BioSciences, Inc. will post ($5.13) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/08/12/coherus-biosciences-inc-chrs-insider-sells-263375-70-in-stock.html.

A number of brokerages have recently issued reports on CHRS. Cowen and Company restated an “outperform” rating and issued a $45.00 price target on shares of Coherus BioSciences in a research report on Tuesday, June 13th. Citigroup Inc. dropped their price target on shares of Coherus BioSciences from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, June 13th. Robert W. Baird lowered their price objective on shares of Coherus BioSciences from $40.00 to $37.00 and set an “outperform” rating for the company in a research note on Tuesday, June 13th. BMO Capital Markets assumed coverage on shares of Coherus BioSciences in a research note on Friday, May 5th. They issued an “outperform” rating and a $54.00 price objective for the company. Finally, Maxim Group lowered their price objective on shares of Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, June 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $35.90.

Institutional investors have recently bought and sold shares of the company. Jennison Associates LLC increased its position in Coherus BioSciences by 0.4% in the second quarter. Jennison Associates LLC now owns 18,200 shares of the biotechnology company’s stock worth $261,000 after buying an additional 69 shares during the period. Wells Fargo & Company MN increased its position in Coherus BioSciences by 0.9% in the second quarter. Wells Fargo & Company MN now owns 29,116 shares of the biotechnology company’s stock worth $418,000 after buying an additional 253 shares during the period. Nationwide Fund Advisors increased its position in Coherus BioSciences by 1.3% in the first quarter. Nationwide Fund Advisors now owns 33,982 shares of the biotechnology company’s stock worth $719,000 after buying an additional 421 shares during the period. Legal & General Group Plc increased its position in Coherus BioSciences by 12.6% in the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after buying an additional 1,046 shares during the period. Finally, Pictet Asset Management Ltd. increased its position in Coherus BioSciences by 0.3% in the first quarter. Pictet Asset Management Ltd. now owns 441,788 shares of the biotechnology company’s stock worth $9,344,000 after buying an additional 1,432 shares during the period. Institutional investors and hedge funds own 72.07% of the company’s stock.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Insider Buying and Selling by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply